logo
Sign in

Ginkgo Bioworks

BOSTON, MA · Biotech · Public

Cloud-based autonomous laboratory platform that executes biological experiments programmatically

Claim this profile

Follows are private to you and power your alerts

Updated · ginkgobioworks.com

Sector
Biotech
Headquarters
BOSTON, MA
Latest Form D
$50M, Jul 2015
Total capital
$241M
Federal grants
None on recordNo awards found in SBIR/STTR, NIH, NSF or DoD records.
Private capital raised
$50M
1 Form D · last Jul 2015
135 months since last filing
Federal contracts
$191M
19 awards · Defense, Health and Human S
Rank in Biotech#5 of 4373
Granted patents
11
29 pending · first 2024
Rank in peer group#9 of 342

Capital timeline

20112013201520172019202120232025FEDERAL ↑EQUITY ↓Cumulative $241M$10.4M$5.3M$6.6M$5.9M$62.6M$74.7M1st Form D$50M
2011201520192023FEDERAL ↑EQUITY ↓Cumulative $241M$10.4M$6.6M$62.6M$74.7M1st Form D$50M

Latest events

  • Federal contractHealth and Human S · Metagenomic Next-generation Sequencing (mngs)$3.2M
  • Federal contractHealth and Human S · Traveler-based Genomic Surveillance Program$74.7M
  • Federal contractHealth and Human S · Test Surge And Data Sharing Multiple Award Idiq$450K
  • Federal contractHealth and Human S · Test Surge And Data Sharing Multiple Award Idiq$775K
  • Federal contractHealth and Human S · Test Surge And Data Sharing Multiple Award Idiq$2.5M
  • Federal contractHealth and Human S · Traveler-based Genomic Surveillance$1.2M
  • Federal contractDefense · Darpa Ice Control For Cold Environments (ice)$5.2M
  • Private capital raisedForm D · SEC · 1st filing$50M
Show 12 earlier federal awards
  • Federal contractDefense · Dna Recording Intrinsic Cellular Biointelligence (drinc Bio)$1.8M
  • Federal contractDefense · Darpa Contract Award (base) "superb: Synbio + Universal Purification Of Extract-derived, Right-on-time Biologics"$4.8M
  • Federal contractHealth and Human S · Airport Genomic Testing$62.6M
  • Federal contractDefense · The Revector Program Aims To Develop Methods To Use Human Skin Microbiomes To Modulate Chemical Production In Order To Avoid Mosquito Attraction And Feeding And Reduce The Threat Of Mosquito-borne Disease To Warfighters.$5.9M
  • Federal contractHealth and Human S · Rapid Acceleration Of Diagnostics (radx) Advanced Technology Platforms (atp)- The Radx-atp Program Seeks To Increase Testing Capacity And Throughput By Identifying Existing Testing Platforms For SARS-COV-2 Testing.$6.6M
  • Federal contractDefense · Igf::ot::igf Iarpa Felix Program$5.3M
  • Federal contractDefense · Start Of Contract Meeting$1K
  • Federal contractDefense · Igf::ot::igf Ginkgo Bioworks SD2 Program. The Purpose Of This Action Is To Award Phase I. Ginkgo Bioworks Shall Act As A TA3 SD2 Performer, Developing Software Interfaces To Transition Generated Synthetic Biological Test Results To Other Software Systems.$10.4M
  • Federal contractDefense · Igf::ot::igf Darpa SBIR Phase II Entitled "controlling Antibiotic Resistance By Vaccinating Bacterial Populations"$1.8M
  • Federal contractDefense · Darpa SBIR Phase I Effort Entitled, "controlling Antibiotic Resistance By Vaccinating Bacterial Populations".$150K
  • Federal contractDefense · Research&development Iaw The Sow Titled "environment-dependent Copy Protection Of Engineered Industrial Organisms"$3.2M
  • Federal contractDefense · This Effort Represents A Feasibility Study That If Successful Enables Routine Quantifiable Characterization Of Protein Levels Essential To The Development Of An Efficient And Reliable Cad Tools For Synthetic Biology. The Research Conducted Under This Effort Has Vast Applications Both Within DOD And Private Sector Including Optimized Synthetic Biofuels, Novel Materials, Food Production And Medicines.$500K

Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.

Federal first

45months

from Ginkgo Bioworks’s first federal award to its first private round.

First federal award · Oct 2011
Defense · $500K
First Form D · Jul 2015
$50M · 1st Form D
Awards before first raise
4 awards

An association in public records, not a cause or a prediction.

Standing among 342 peers

Line = median

Biotech · Platform

  • Granted patents#9 · top 3%

Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.

Founders and team

From SEC Form D filings
  • Bartholomew CantonExecutive OfficerNamed in SEC Form D filings
  • Jason KellyDirector, Executive OfficerNamed in SEC Form D filings
  • Peter BoyntonDirectorNamed in SEC Form D filings
  • Reshma ShettyDirector, Executive OfficerNamed in SEC Form D filings

What it has protected

USPTO · 11 granted of 40
Show all 40 patent records
  • Scalable, Mobile, And Reconfigurable Modules For Processing Biological And Chemical MaterialsJul 7, 2026 · US 12,674,810Granted
  • Production Of Proteins, Including Secreted ProteinsMar 26, 2026 · Application 19110994Pending
  • Scalable, Mobile, And Reconfigurable Modules For Processing Biological And Chemical MaterialsNov 13, 2025 · Application 19213714Pending
  • Engineered Phenylalanine Ammonia Lyase And Tyrosine Ammonia Lyase Enzymes For Producing Aromatic CompoundsOct 23, 2025 · Application 18868926Pending
  • Biosynthesis Of Cannabinoids And Cannabinoid PrecursorsSep 11, 2025 · Application 18859980Pending
  • Biosynthesis Of Cannabinoids And Cannabinoid PrecursorsJun 26, 2025 · Application 18849234Pending
  • Compositions And Methods For Controlling Plant Pests And Improving Plant HealthJun 5, 2025 · Application 19036199Pending
  • Gene Therapy For Arrhythmogenic CardiomyopathyMay 8, 2025 · Application 18838928Pending
  • Antibody-evading Virus VectorsMar 20, 2025 · Application 18797183Pending
  • Biosynthesis Of Oxygenated HydrocarbonsMar 6, 2025 · Application 18830141Pending
  • Compositions And Methods For Controlling Plant Pests And Improving Plant HealthMar 4, 2025 · US 12,239,137Granted
  • Biosynthesis Of MogrosidesFeb 25, 2025 · US 12,234,464Granted
  • Biosynthesis Of Cannabinoids And Cannabinoid PrecursorsNov 21, 2024 · Application 18696714Pending
  • Virus Vectors For Targeting Ophthalmic TissuesOct 15, 2024 · US 12,116,384Granted
  • Antibody-evading Virus VectorsSep 17, 2024 · US 12,091,435Granted
  • Chimeric Terpene SynthasesSep 3, 2024 · US 12,077,799Granted
  • Antibody-evading Virus VectorsAug 13, 2024 · US 12,060,390Granted
  • Gene Therapy For Angelman SyndromeAug 8, 2024 · Application 18435561Pending
  • Compositions And Methods For Improving Plant Health And Controlling Plant DiseaseAug 1, 2024 · Application 18561952Pending
  • Intergeneric Endospore Display Platforms, Products And MethodsJul 11, 2024 · Application 18563054Pending
  • Biosynthesis Of Isoprenoids And Precursors ThereofJul 4, 2024 · Application 18285138Pending
  • Genetically Modified Yeast Cells And Methods Of Use For Increased Lipid YieldJun 20, 2024 · Application 18288954Pending
  • Biosynthesis Of MogrosidesJun 20, 2024 · Application 18285018Pending
  • Production Of Vaccinia Capping EnzymeJun 6, 2024 · Application 18284673Pending
  • Biosynthesis Of MogrosidesMay 16, 2024 · Application 18281479Pending
  • Recombinant Adeno-associated Virus VectorsMay 14, 2024 · US 11,981,914Granted
  • Antibody-evading Virus VectorsMay 7, 2024 · US 11,976,096Granted
  • Organophosphorus Nerve Agent Hydrolyzing EnzymesMay 2, 2024 · Application 18283688Pending
  • Biosynthesis Of Cannabinoids And Cannabinoid PrecursorsApr 4, 2024 · Application 18031522Pending
  • Recombinant Bacteria Engineered To Treat Diseases Associated With Methionine Metabolism And Methods Of Use ThereofMar 28, 2024 · Application 18524651Pending
  • Methods And Compositions For Reducing Index HoppingMar 21, 2024 · Application 18018401Pending
  • Heterologous Production Of 10-METHYLSTEARIC AcidMar 14, 2024 · Application 18227147Pending
  • Adeno-associated Viral Vectors For Treatment Of Niemann-pick Disease Type-cFeb 20, 2024 · US 11,905,523Granted
  • Biosynthesis Of Cannabinoids And Cannabinoid PrecursorsJan 25, 2024 · Application 18015046Pending
  • Oleic Acid Production In YeastJan 25, 2024 · Application 18138472Pending
  • Synthetic Methanol Inducible Promoters And Uses ThereofJan 4, 2024 · Application 18037215Pending
  • Recombinant Bacteria Engineered To Treat Diseases Associated With Methionine Metabolism And Methods Of Use ThereofJan 2, 2024 · US 11,859,189Granted
  • Adeno-associated Viral Vectors For Treatment Of Niemann-pick Disease Type CDec 7, 2023 · Application 17769621Pending
  • Chemoautotrophic Cells Comprising An Engineered Carbon Fixation PathwayNov 30, 2023 · Application 18326495Pending
  • Methods And Compositions Involving Promoters Derived From Yarrowia LipolyticaNov 9, 2023 · Application 18146661Pending

Related companies, and why

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.

Sources

Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.

How to read this page

Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.

Data freshness

SEC Form D filings through . SBIR and STTR awards through .